Developing new methods for activating carbon bonds in organic compounds
New Strategies and Reactions for the α-C–H Functionalization and Hydrofunctionalization of Carbon–Carbon Multiple Bonds
This study is exploring new, eco-friendly ways to make important building blocks for medicines more easily, using special iron-based tools, to help speed up the creation of new drugs that can improve health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10875413 on NIH RePORTER |
What this research studies
This research focuses on creating innovative organic methods to activate carbon-carbon double and triple bonds, which are crucial in many biomedical compounds. By utilizing iron-based catalysts and novel reagents, the project aims to streamline the synthesis of complex molecules that can be used in drug discovery. The approach involves generating specific reactive intermediates that can lead to the formation of important chemical bonds, enhancing the efficiency of producing pharmaceuticals. Overall, this work seeks to accelerate the development of new drugs and improve public health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals with conditions that could be treated by new pharmaceuticals developed through these innovative methods.
Not a fit: Patients who are not seeking new treatment options or those with conditions that do not require pharmaceutical intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more efficient drug development processes, ultimately benefiting patients through the availability of new treatments.
How similar studies have performed: Other research in the field of organic chemistry has shown success with similar catalytic methods, indicating a promising potential for this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Wang, Yiming — University of Pittsburgh at Pittsburgh
- Study coordinator: Wang, Yiming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.